5.32
4.32%
-0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire Inc.
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The Motley Fool
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Zacks Investment Research
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
Wall Street Breakfast: The Week Ahead
Seeking Alpha
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Zacks Investment Research
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Zacks Investment Research
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
GlobeNewswire Inc.
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire Inc.
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Zacks Investment Research
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The Motley Fool
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The Motley Fool
The Latest Analyst Ratings For Editas Medicine
Benzinga
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
Zacks Investment Research
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
Benzinga
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates
Zacks Investment Research
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
GlobeNewswire Inc.
Bayer (BAYRY) Intends to Slash Dividends Amid Challenges
Zacks Investment Research
Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade
Zacks Investment Research
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
Zacks Investment Research
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
Zacks Investment Research
5 Biotech Stocks to Consider for Your Portfolio in 2024
Zacks Investment Research
What Makes Editas (EDIT) a New Buy Stock
Zacks Investment Research
2 Under-the-Radar Stocks With Incredible Upside Potential
The Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
The Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
The Motley Fool
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
The Motley Fool
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
Zacks Investment Research
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
The Motley Fool
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
Zacks Investment Research
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics
Zacks Investment Research
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
Zacks Investment Research
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%
Zacks Investment Research
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
Zacks Investment Research
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
MarketWatch
3 Biotechs With Promising Gene Therapies in the Spotlight
Zacks Investment Research
The Latest Analyst Ratings for Editas Medicine
Benzinga
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
GlobeNewswire Inc.
Bull of the Day: CRISPR Therapeutics (CRSP)
Zacks Investment Research
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
MarketWatch
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
MarketWatch
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
MarketWatch
1 Promising Stock Down 66% That Could Skyrocket in 2024
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The Motley Fool
Capitalizzazione:
|
Volume (24 ore):